Eccogene and AstraZeneca to Present Elecoglipron Clinical Data at ADA 2026
核心洞察
Eccogene (搜索) will present Phase 1b data for elecoglipron (搜索) (AZD5004/ECC5004), an oral GLP-1 receptor (搜索) agonist, in Chinese adults with obesity (搜索) or overweight (搜索) with or without type 2 diabetes (搜索) at ADA 2026.
AstraZeneca, which holds global rights to elecoglipron (搜索) outside Greater China, will present Phase 2b data from two global studies including the VISTA obesity (搜索) trial and SOLSTICE diabetes trial.
The presentations mark a pivotal moment for Eccogene (搜索)'s oral small-molecule GLP-1 receptor (搜索) agonist program, demonstrating momentum in developing next-generation therapeutics for cardiometabolic conditions.
Eccogene (搜索), a clinical-stage biopharmaceutical company developing next-generation oral small molecule therapeutics for chronic cardiometabolic and inflammatory conditions, announced that data from a Phase 1b study conducted in China evaluating elecoglipron (搜索) (AZD5004/ECC5004), an oral small-molecule GLP-1 receptor (搜索) agonist, will be presented in a late-breaking poster presentation at the 2026 Scientific Sessions of the American Diabetes Association (ADA). The ADA's 2026 Scientific Sessions will take place June 5-8 at the Ernest N. Morial Convention Center in New Orleans, Louisiana.
AstraZeneca, which has in-licensed global rights to elecoglipron (搜索) outside Greater China, will present Phase 2b data from two global studies of elecoglipron during an ADA symposium.
Phase 1b Study in Chinese Population
Eccogene (搜索)'s late-breaking poster presentation will focus on safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of elecoglipron (搜索) in Chinese adults living with obesity (搜索) or overweight (搜索) with or without type 2 diabetes (搜索). The presentation will be delivered by Jai Patel, MBBS, MRCP(UK), Chief Medical Officer of Eccogene Inc., on Sunday, June 7, 2026, from 12:30 p.m. to 1:30 p.m. CT in Poster Hall (Halls D-E) as poster number 2844-LB.
AstraZeneca Phase 2b Program
AstraZeneca will present Phase 2b data from two global studies during a dedicated symposium titled "AZD5004, A Novel Oral Small Molecule GLP-1 Receptor (搜索) Agonist: Overweight (搜索)/Obesity (搜索) (VISTA) and Type 2 Diabetes (搜索) (SOLSTICE) Phase 2 Trial Results." The symposium is scheduled for Monday, June 8, 2026, from 3:15 p.m. to 4:15 p.m. CT in Great Hall A (Level 1).
The first presentation will focus on the VISTA study, described as a Phase 2b randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of AZD5004 in participants living with obesity (搜索) or overweight (搜索) with comorbidity. This presentation is scheduled from 3:15 p.m. to 3:35 p.m. CT.
Strategic Partnership and Development
"We are excited to showcase the rapid progress of elecoglipron (搜索) at the ADA's 2026 Scientific Sessions, marking a pivotal moment for Eccogene (搜索) on the global stage," said Jingye Zhou, Ph.D., Chief Executive Officer of Eccogene. "The presentation of our late-breaking Phase 1b data alongside AstraZeneca's Phase 2b symposium underscores the momentum behind this program. It is a testament to our shared commitment to advancing elecoglipron to deliver clinically meaningful results for patients worldwide."
The collaboration between Eccogene (搜索) and AstraZeneca represents a strategic approach to developing oral GLP-1 receptor (搜索) agonists, with Eccogene maintaining rights in Greater China while AstraZeneca holds global rights outside this region. The presentations at ADA 2026 will provide insights into the clinical development progress of this oral small-molecule approach to GLP-1 receptor activation across different patient populations and geographic regions.